Core Laboratories Inc. (CLB)
NYSE: CLB · Real-Time Price · USD
16.77
-0.52 (-3.01%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Core Laboratories Earnings Call Transcripts

Fiscal Year 2025

  • Fourth quarter revenue rose 3% sequentially and 7% year-over-year, with strong international demand offsetting US softness. Margins were pressured by tariffs, bad debt, and weather disruptions, but capital discipline and share buybacks continued. Guidance for Q1 2026 anticipates revenue of $124–$130 million and EPS of $0.11–$0.15.

  • Q3 2025 saw over 3% sequential revenue growth, margin expansion, and strong international demand, with $5 million returned to shareholders via buybacks. Outlook remains constructive, with Q4 revenue projected at $132–$136 million and EPS of $0.18–$0.22.

  • Q2 2025 saw 5% sequential revenue growth, margin expansion, and strong free cash flow, with international demand and new technology deployments offsetting U.S. market softness. Guidance for Q3 projects stable revenue and continued focus on shareholder returns.

  • Q1 2025 saw revenue and earnings decline due to seasonality and expanded sanctions, but operational efficiencies and cost controls helped mitigate impacts. Guidance for Q2 anticipates revenue growth and margin improvement, with international markets expected to remain resilient.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Powered by